• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用同基因照射的、负载HIV-1包膜衍生肽的树突状细胞免疫诱导CD8 + 细胞毒性T淋巴细胞。

Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.

作者信息

Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky J A

机构信息

Department of Microbilogy and Immunology, Nippon Medical School, Tokyo, Japan.

出版信息

Int Immunol. 1993 Aug;5(8):849-57. doi: 10.1093/intimm/5.8.849.

DOI:10.1093/intimm/5.8.849
PMID:8398980
Abstract

Based on the evidence that CD8+ cytotoxic T cells (CTL) precursors do not appear to distinguish between virus-infected cells and viral peptide-pulsed syngeneic cells, we have developed methods for priming class I MHC molecule restricted CD8+ CTL with such peptides without using any adjuvant. We were able to prime in vivo such CTL immunity lasting at least 6 months with a single i.v. injection of syngeneic 2200-3300 rad irradiated peptide-pulsed spleen cells, and even more efficiently with a very small number of irradiated class II MHC molecule expressing splenic dendritic cells (DC). No foreign serum source was necessary during the pulsing. Interestingly, we could not generate significant CTL activity with unirradiated or low dose (< 1100 rad) irradiated spleen cells. Because even purified DC required irradiation for optimal activity, because unirradiated B cells did not significantly inhibit the immunization with DC, and because B cell depletion did not substitute for irradiation, we believe that the effect of irradiation is more to determine homing of the cells than to eliminate interference by B cells. Intravenous immunization was much more effective than s.c. or i.p. immunization. CTL generated by this method could kill both peptide-pulsed syngeneic targets and targets endogenously expressing the whole gp160 gene. Moreover, we found that we could prime CD8+ CTL with the minimal 10-residue core peptide (RGPGRAFVTI) for optimal presentation by class I MHC molecules as efficiently as the original p18. These results suggested that DC bearing antigenic peptide may prime antigen-specific CD8+ CTL in vivo. These results offer useful information for development of synthetic peptide vaccines and immunotherapy.

摘要

基于CD8 + 细胞毒性T细胞(CTL)前体似乎无法区分病毒感染细胞和病毒肽脉冲同基因细胞的证据,我们开发了在不使用任何佐剂的情况下用此类肽引发I类MHC分子限制性CD8 + CTL的方法。我们能够通过单次静脉注射同基因的2200 - 3300拉德照射的肽脉冲脾细胞在体内引发持续至少6个月的此类CTL免疫,甚至用极少量表达II类MHC分子的照射脾树突状细胞(DC)引发效率更高。脉冲期间无需外源血清。有趣的是,我们用未照射或低剂量(<1100拉德)照射的脾细胞无法产生显著的CTL活性。因为即使纯化的DC也需要照射以获得最佳活性,因为未照射的B细胞不会显著抑制DC免疫,并且因为B细胞耗竭不能替代照射,我们认为照射的作用更多是决定细胞的归巢而不是消除B细胞的干扰。静脉免疫比皮下或腹腔免疫更有效。通过这种方法产生的CTL可以杀死肽脉冲同基因靶细胞和内源性表达整个gp160基因的靶细胞。此外,我们发现我们可以用最小的10个残基核心肽(RGPGRAFVTI)引发CD8 + CTL,以便I类MHC分子进行最佳呈递,其效率与原始p18相同。这些结果表明携带抗原肽的DC可能在体内引发抗原特异性CD8 + CTL。这些结果为合成肽疫苗和免疫疗法的开发提供了有用信息。

相似文献

1
Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells.用同基因照射的、负载HIV-1包膜衍生肽的树突状细胞免疫诱导CD8 + 细胞毒性T淋巴细胞。
Int Immunol. 1993 Aug;5(8):849-57. doi: 10.1093/intimm/5.8.849.
2
Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.与来源于1型人类免疫缺陷病毒(HIV)V3环的肽结合的流产布鲁氏菌可在正常和CD4⁺细胞耗竭的BALB/c小鼠中诱导HIV特异性细胞毒性T细胞反应。
J Virol. 1996 May;70(5):3084-92. doi: 10.1128/JVI.70.5.3084-3092.1996.
3
Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.人类免疫缺陷病毒1型包膜蛋白的细胞毒性T细胞表位与多种I类组织相容性分子的广泛识别
J Immunol. 1992 Mar 15;148(6):1657-67.
4
Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.通过接种重组蛋白抗原引发I类限制性细胞毒性T淋巴细胞。
Vaccine. 1995 Jun;13(9):857-65. doi: 10.1016/0264-410x(94)00038-o.
5
Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.细胞毒性T细胞库选择。单个氨基酸决定替代性I类限制。
J Immunol. 1994 Jun 15;152(12):5603-12.
6
An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.一种内源性合成的十聚体肽可有效激活针对HIV-1包膜糖蛋白的细胞毒性T细胞。
Eur J Immunol. 1993 Nov;23(11):2777-81. doi: 10.1002/eji.1830231109.
7
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.体内使用肽疫苗构建体引发抗HIV CD8 + 细胞毒性T淋巴细胞(CTL)时所需的辅助性细胞毒性T淋巴细胞(CTL)决定簇连接。
J Immunol. 1994 Jan 15;152(2):549-56.
8
Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism?游离抗原肽对人免疫缺陷病毒(HIV)-1包膜特异性CD8 + 细胞毒性T淋巴细胞的失活作用:一种自我否决机制?
J Exp Med. 1996 Mar 1;183(3):879-89. doi: 10.1084/jem.183.3.879.
9
Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.在接受候选HIV-1疫苗免疫的血清阴性个体中诱导针对人类免疫缺陷病毒1型(HIV-1)gp120高度保守区域的主要组织相容性复合体I类限制性细胞毒性T淋巴细胞反应。
J Virol. 1994 May;68(5):3145-53. doi: 10.1128/JVI.68.5.3145-3153.1994.
10
Preferential V beta usage by cytotoxic T cells cross-reactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction.细胞毒性T细胞对HIV-1 gp160的两个表位具有交叉反应性且在I类主要组织相容性复合体限制方面存在简并性,这些细胞毒性T细胞优先使用Vβ。
J Immunol. 1993 Aug 15;151(4):2283-95.

引用本文的文献

1
Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.纳米载体中免疫刺激物质的递送可增强抗肿瘤纳米疫苗的疗效。
Int J Mol Sci. 2023 Jul 29;24(15):12174. doi: 10.3390/ijms241512174.
2
Exosomes in Immune Regulation.免疫调节中的外泌体
Noncoding RNA. 2021 Jan 8;7(1):4. doi: 10.3390/ncrna7010004.
3
Dendritic Cell-Based Cancer Vaccines.基于树突状细胞的癌症疫苗。
J Immunol. 2018 Jan 15;200(2):443-449. doi: 10.4049/jimmunol.1701024.
4
Suppression of murine tumour growth through CD8 cytotoxic T lymphocytes via activated DEC-205 dendritic cells by sequential administration of α-galactosylceramide in vivo.通过在体内序贯给予α-半乳糖神经酰胺,经活化的DEC-205树突状细胞介导CD8细胞毒性T淋巴细胞抑制小鼠肿瘤生长。
Immunology. 2017 Jul;151(3):324-339. doi: 10.1111/imm.12733. Epub 2017 Apr 18.
5
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.妇科肿瘤学组进行的两项 p53 肽疫苗方法的 II 期临床试验:高复发风险卵巢癌患者的皮下注射和静脉内脉冲树突状细胞。
Cancer Immunol Immunother. 2012 Mar;61(3):373-84. doi: 10.1007/s00262-011-1100-9. Epub 2011 Sep 17.
6
Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.新型重组牛分枝杆菌、绵羊腺病毒和改良安卡拉痘苗病毒联合疫苗可诱导恒河猴产生强烈的人免疫缺陷病毒特异性 CD4 和 CD8 T 细胞应答。
J Virol. 2010 Jun;84(12):5898-908. doi: 10.1128/JVI.02607-09. Epub 2010 Apr 7.
7
Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.通过选择性刺激先天 DEC-205(+)树突状细胞,诱导针对已建立肿瘤的肿瘤特异性获得性免疫。
Cancer Immunol Immunother. 2010 Jul;59(7):1083-95. doi: 10.1007/s00262-010-0835-z. Epub 2010 Mar 10.
8
Neurons preferentially respond to self-MHC class I allele products regardless of peptide presented.神经元优先对自身 MHC Ⅰ类等位基因产物产生反应,而与呈递的肽无关。
J Immunol. 2010 Jan 15;184(2):816-23. doi: 10.4049/jimmunol.0902159. Epub 2009 Dec 16.
9
Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells.γ射线照射会改变CD4+CD25+调节性T细胞的表型和功能。
Cell Biol Int. 2009 May;33(5):565-71. doi: 10.1016/j.cellbi.2009.02.007. Epub 2009 Mar 4.
10
Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors.激活方式和给药途径均决定了骨髓来源的树突状细胞在次级淋巴器官中积聚以及启动CD8 + T细胞对抗肿瘤的能力。
Cancer Immunol Immunother. 2008 Jan;57(1):63-71. doi: 10.1007/s00262-007-0350-z. Epub 2007 Jul 3.